Gepotidacin (Blujepa) — A New Antibiotic for Uncomplicated UTI
Abstract
The FDA has approved gepotidacin (Blujepa – GSK), a triazaacenaphthylene bacterial type II topoisomerase inhibitor, for oral treatment of uncomplicated urinary tract infections (uUTI) in female patients ≥12 years old who weigh ≥40 kg. Gepotidacin is the first triazaacenaphthylene antibiotic to be approved in the US.
Fields of Study & Subjects
Urinary Tract Infections Management
Cancer therapeutics and mechanisms
Bladder and Urothelial Cancer Treatments
Publication details
- Journal / source
- The medical letter on drugs and therapeutics/The medical letter
- Volume
- 68
- Issue
- 1745
- Pages
- 1–3
- Publication date
- 5 January 2026
- Language
- EN